olorectal cancer is the third most commonly diagnosed cancer in the United States, with approximately 145,000 new cases and 56,300 deaths projected for 2005. 1 An intensive search to identify chemopreventive agents as a means to reduce the complications and deaths due to colorectal cancer has revealed aspirin and other nonsteroidal antiinflammatory drugs (NSAIDs) as attractive candidates, 2-6 although concern about toxicity may limit broad application of these agents.
The rate-limiting enzyme in mevalonate synthesis is 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. 7, 8 The statins are a class of agents designed to inhibit HMG-CoA reductase, and they are effective in the management of hypercholesterolemia. Owing to the involvement of HMG-CoA reductase in cholesterol synthesis and growth control, statins may have chemopreventive activity against cancer. 9 In vitro data support a potential role for the use of statins in colorectal cancer. HMG-CoA reductase is overexpressed in colorectal-cancer cells, 10 and statins have been shown to induce apoptosis in cancer cell lines in vitro. 11, 12 Several randomized clinical trials designed to assess the safety of statins and cardiovascular outcomes among patients receiving them have also assessed the incidence of cancer. The results were not consistent: in some trials, more cases of cancer occurred among patients treated with statins than among those who did not receive these agents, and in other trials, fewer cases occurred. [13] [14] [15] [16] [17] [18] [19] [20] [21] Since all these studies were designed to assess end points related to cardiovascular disease, the small numbers of cancers observed limit their statistical power to detect associations between statin use and the risk of cancer. To clarify this association, we evaluated data gathered in a population-based, epidemiologic, case-control study.
participants
The Molecular Epidemiology of Colorectal Cancer study is a population-based case-control study of incident colorectal cancer in northern Israel. Patients were eligible for participation if they had received a diagnosis of colorectal cancer between May 31, 1998, and March 31, 2004 , and lived in a geographically defined area of northern Israel. Controls were identified from the same source population with the use of the Clalit Health Services (CHS) database.
CHS is the largest health care provider in Israel and covers approximately 70 percent of the older population (persons at least 60 years of age). Health care coverage in Israel is mandated and is provided by four groups akin to health maintenance organizations. Thus, all study participants (patients and controls) had similar health insurance and similar access to health services. Controls were individually matched to patients according to the year of birth, sex, primary clinic location, and ethnic group (Jewish vs. non-Jewish). Potential controls were excluded if they had a history of colorectal cancer. Participants provided written informed consent at the time of enrollment.
Participants were interviewed to obtain demographic information and information about their personal and family history of cancer, reproductive history, medical history, medication use, and health habits; they also completed a dietary questionnaire. Diagnoses of colorectal cancer were confirmed by means of a standardized pathological review by one pathologist. The institutional review boards at the Carmel Medical Center, Haifa, and the University of Michigan, Ann Arbor, approved all procedures.
exposure data
Participants were asked to recall each medication they had used for at least five years, and statin use was determined on the basis of this list. The use of aspirin and other NSAIDs was also assessed; information gathered included dose, duration of use, and indication for use. For analyses of aspirin or other NSAIDs, exposure was defined as five or more years of total use, and no exposure was defined as less than five years of use or no use.
A complete, three-generation pedigree and information on the family history of cancer were also recorded for each participant. The report of colon or rectal cancer in at least one first-degree relative was considered to represent a family history of colorectal cancer. Assessment of physical activity was based on a validated instrument 22 used to evaluate three dimensions of physical activity: sports, leisure, and occupational activities. Sports activity was the dimension considered in these analyses since it is the dimension most strongly associated with colorectal cancer in this analysis.
Ethnic group was determined by assessing participants' religious affiliation, self-described ethnic group, and the country of birth of their parents and grandparents. Ashkenazi Jewish heritage was determined as previously described. 23 Comprehensive dietary histories were obtained with the use of a validated food-frequency questionnaire modified for the Israeli diet. Vegetable consumption was categorized into three groups on the basis of the number of servings consumed per day in the control group (fewer than 5.2, 5.2 to 7.5, and more than 7.5 servings per day). The lowest category of consumption was used as the reference category. Red-meat consumption was also categorized into three groups on the basis of the number of servings consumed per day in the control group. A participant's history of medical conditions was elicited by asking whether he or she had ever received a diagnosis of any of 15 medical conditions, including hypercholesterolemia, ischemic heart disease, and inflammatory bowel disease.
validation of statin use
Participants' reports of statin use were matched against CHS prescription records to verify use. Prescription records were available for 1998 through 2004 and included the number of prescriptions filled per year. The prescription file was started in 1998, so any prescriptions filled before 1998 could not be validated by this means. Prescription records for statins during the year before diagnosis were reviewed for all patients who were invited to participate in the study; for controls, prescription records during the year before enrollment in the study were reviewed. In this way, potential differences between participating and nonparticipating patients and controls in terms of statin use were evaluated.
statistical analysis
Statistical analyses were performed with the use of SAS software (version 8.2), and all reported P values are two-sided. A contingency table was used to assess crude associations between statin use and the risk of colorectal cancer. Stratified analyses and unconditional logistic regression were used to assess the association between statin use and the risk of colorectal cancer, to adjust for confounding, and to identify any potential effect modification. To account for the study design, matched analyses were percent vs. 6.1 percent) and was associated with a significant reduction in the risk of colorectal cancer (odds ratio, 0.50; 95 percent confidence interval, 0.40 to 0.63) ( Table 2 ). After adjustment for potential confounders (including age; sex; the use or nonuse of aspirin or other NSAIDs; ethnic group; the presence or absence of sports participation, hypercholesterolemia, and a history of colorectal cancer in a first-degree relative; and level of vegetable consumption), the association between statins and the reduced risk of colorectal cancer remained significant. The level of education and level of red-meat consumption were also evaluated as potential confounders but were not included in the final model, since they did not measurably influence the odds ratio. Matched analyses of 1651 pairs revealed that the crude and adjusted odd ratios for statin use were similar in magnitude to those found in the unmatched analysis and remained significant (Table  3) . When the analysis was limited to the 1520 patients who were members of CHS, the association was unchanged (odds ratio, 0.50; 95 percent confidence interval, 0.39 to 0.64). The frequency of statin use increased with increasing year of detection among both patients (P for trend=0.08) and controls (P for trend=0.02). After controlling for the year of detection, we found that the association between statin use and the reduced risk of colorectal cancer remained virtually unchanged (odds ratio, 0.51; 95 percent confidence interval, 0.40 to 0.64). Simvastatin and pravastatin were the two most commonly used statins in this population, accounting for 55.6 percent and 41.5 percent of use, respectively. In unadjusted analyses, the strength of the association between statin use (vs. no statin use) and a reduced risk of colorectal cancer was similar for simvastatin (odds ratio, 0.49; 95 percent confidence interval, 0.36 to 0.67) and pravastatin (odds ratio, 0.44; 95 percent confidence interval, 0.31 to 0.63).
To assess whether the association was due to a general effect of cholesterol lowering or to a specific effect of statins, we also evaluated the association between other cholesterol-lowering drugs and the risk of colorectal cancer. Twenty-one patients and 20 controls used the fibric-acid derivative bezafibrate. There was no significant association between bezafibrate use and the risk of colorectal cancer (odds ratio, 1.08; 95 percent confidence interval, 0.59 to 2.01). It is worthwhile to note that only 1 percent of the study population reported using bezafibrate, so it is unlikely that we would be able to identify small effects associated with the use of fibric-acid derivatives. No other class of cholesterol-lowering agent or specific drug was reported as being commonly used.
After adjustment for the use of aspirin or other NSAIDs for at least five years as well as other risk factors for colorectal cancer, statin use was still associated with a significant reduction in the risk of colorectal cancer (odds ratio, 0.55; 95 percent confidence interval, 0.40 to 0.74) ( Table 4) . Because of reports of a synergistic effect in vitro between NSAIDs and statins, we evaluated whether the use of aspirin or other NSAIDs modified the protective effect of statins. We could find no evidence of an effect modification on a multiplicative scale (P=0.36).
A stratified analysis was performed to determine whether statins appeared equally protective among patients with and those without a family history of colorectal cancer. The protective association remained significant among patients with a family history of colorectal cancer (odds ratio, 0.41; 95 percent confidence interval, 0.19 to 0.93), and we noted no interaction between family history and statin use (P for interaction=0.67).
We analyzed the data separately for cancers of the colon and the rectum and observed a significant inverse association for both (Table 3) . Statin users were almost as likely as nonusers to have colorectal cancer diagnosed at an early stage of disease (stage I or II) as compared with a later stage (stage III or IV) (odds ratio, 0.90; 95 percent confidence interval, 0.54 to 1.50; P=0.69). Colorectal cancer was somewhat less likely to be poorly differentiated among statin users (6.4 percent) than among nonusers (8.6 percent), although this difference was not significant (P=0.48).
* CI denotes confidence interval.
† Analyses were adjusted for age; sex; use or nonuse of aspirin or other NSAIDs; ethnic group; the presence or absence of sports participation, hypercholesterolemia, and a history of colorectal cancer in a first-degree relative; and level of vegetable consumption. To evaluate the possibility of confounding by indication, we investigated statin use and the risk of colorectal cancer among patients who reported a previous diagnosis of hypercholesterolemia or ischemic heart disease, and the protective effect of statins was similar in these patients (Table 5 ). Because of our interest in the antiinflammatory properties of statins, we also examined the relationship between statin use and the risk of colorectal cancer among 55 patients with inflammatory bowel disease, and we observed a protective effect of statins in this subgroup (P=0.006 for the comparison between users and nonusers of statins) ( Table 5) .
We validated regular statin use on the basis of prescription records from the CHS database for the 286 self-reported statin users who were members of CHS. When we classified regular users of statins as persons who filled a prescription for statins three or more times per year, self-reports were validated for 276 of 286 participants (96.5 percent). Selfreported use could not be confirmed on the basis of prescription records for six patients and four controls.
We also used data from prescription records to evaluate differences in statin use among patients and controls who declined to participate in the study.
The use of statins during the year before diagnosis (for patients) and the year before enrollment (for controls) was compared. No significant difference in the rate of statin use was observed between patients who were interviewed and those who declined to participate (5.2 percent vs. 6.0 percent, P=0.51). The findings were similar among participating controls and those who declined to participate (6.3 percent and 5.7 percent, respectively; P=0.39).
Our data indicate that there is a strong inverse association between the risk of colorectal cancer and the long-term use of statins. This association is consistent with preclinical data suggesting that it is biologically plausible that statins may have a role in colorectal cancer, as well as with evidence from secondary analyses of some, but not all, randomized, controlled trials. These data are also consistent with the results of a small, nested case-control study from Quebec, Canada, that reported a significant reduction in the occurrence of all cancers among statin users as compared with persons who did not use statins (but who did take bile acid-binding resins to lower cholesterol) and a nonsignificant discussion * CI denotes confidence interval.
† Analyses were adjusted for use or nonuse of aspirin or other NSAIDs; ethnic group; the presence or absence of sports participation, hypercholesterolemia, and a history of colorectal cancer in a first-degree relative; and level of vegetable consumption. 28, 29 However, our results do not provide evidence of an interaction between statins and aspirin or other NSAIDs (P for interaction=0.36). Rodent models may not perfectly represent human disease, and it is worth noting that the end point in the rat azoxymethane model is polyp formation rather than the development of colorectal cancer.
Statins have been shown to be associated with an acceptable adverse-effect profile in patients with hypercholesterolemia, 30 with a discontinuation rate of approximately 3 percent owing to such effects. 31 If statins were to be considered for chemopreventive studies in subjects without elevated cholesterol levels, the safety of such an application would need to be evaluated in this population.
We evaluated the potential absolute reduction in the risk of colorectal cancer after treatment with statins by estimating the number of cancers that could be prevented by statin use in both the Israeli population and a high-risk population. In 2002, the age-adjusted incidence of colorectal cancer was 42 per 100,000 Jewish men, 32 and the rate was similar among Jewish women. Using the matched, adjusted odds ratio of 0.53 as an approximation for the relative risk in order to calculate the absolute reduction in risk, 33 we determined that statin therapy could prevent 20.8 cases per 100,000 Jewish men. In the average-risk Israeli population, 4814 persons would need to be treated with statins to prevent one case of colorectal cancer. In a high-risk population, such as those with a family history of colorectal cancer, approximately half as many would need to be treated in order to prevent one case.
Our study has several limitations. Exposure data were collected retrospectively and are therefore sensitive to recall bias. However, since participants are not likely to expect that the use of statins is related to the risk of colorectal cancer, any resulting misclassification is most likely nondifferential and would * CI denotes confidence interval.
† Analyses were adjusted for age; sex; ethnic group; the presence or absence of sports participation, hypercholesterolemia, and a history of colorectal cancer in a first-degree relative; and level of vegetable consumption. tend to attenuate true associations. Furthermore, we were able to validate self-reported statin use through a prescription database. The participation rate was lower among controls than among patients, suggesting the possibility of selection bias. Selection bias seems unlikely, however, since the rate of statin use was similar among those who participated and those who declined. It is also possible that some controls had undiagnosed colorectal cancer, and this type of misclassification would be likely to attenuate any observed association. Assessment of potential confounders was also self-reported; measurement error for these variables could limit our ability to control adequately for confounding. We had very limited information on the dose and duration of use of statins and therefore could not analyze the data for evidence of a dose response. We found that the use of statins is associated with a 47 percent relative reduction in the risk of colorectal cancer after adjustment for other known risk factors and is specific to this class of lipid-lowering agents. Our finding suggests that statins deserve further investigation in chemoprevention and therapeutic clinical trials.
